Results 41 to 50 of about 5,951 (176)

Application of Virtual Twin PBPK Models in Individuals with Obesity via CYP3A4 Phenotyping Using Endogenous Biomarker Data

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 762-773, September 2026.
Plasma 4β‐hydroxycholesterol (4β‐OHC) normalized for the levels of its parent cholesterol (4β‐OHC/C) is an endogenous biomarker for hepatic CYP3A4. This study evaluated CYP3A4 activity longitudinally in individuals while their obesity status was changing. 4β‐OHC/C was measured pre‐surgery (n = 54) and 2 years after Roux‐en‐Y gastric bypass (n = 30) and
Nihan Izat, Haribhau Kangne, Rasmus Jansson‐Löfmark, Jens K. Hertel, Amin Rostami‐Hodjegan, Ida Robertsen, Aleksandra Galetin   +6 more
wiley   +1 more source

From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 648-662, September 2026.
Drug development productivity has not improved despite five decades of computational advancement, with the probability that a compound entering Phase I achieving regulatory approval remaining near 10%. Each automation wave increased throughput while leaving the interpretive bottleneck intact; scientists continued to formulate questions, evaluate ...
Michael McCoy, Matthew McCoy
wiley   +1 more source

Codeine and Metabolite Concentrations in the Breastfed Neonate

Pediatric Anesthesia, Volume 36, Issue 9, Page 1016-1022, September 2026.
ABSTRACT Analgesic effect from codeine is from its metabolite, morphine. Morphine is formed by the O‐demethylation of codeine and that enzyme is controlled by the cytochrome P450 2D6. More than 60 alleles in the CYP2D6 gene have been identified. This spectrum of polymorphism can be categorized into four groups: poor (PM), intermediate (IM), normal (NM),
Brian J. Anderson, Jacqueline A. Hannam
wiley   +1 more source

Development of Physiologically Based Pharmacokinetic (PBPK) Modeling

Pharmaceutics
In this Special Issue, “Development of Physiologically Based Pharmacokinetic (PBPK) Modeling”, readers can find a selection of articles that discuss the most current challenges and advances in this area [...]
Bárbara Sánchez-Dengra, Isabel González-Álvarez   +1 more
openaire   +2 more sources

Plasma Lidocaine Concentrations During Intravenous Lidocaine Infusion Therapy in the Pediatric Population—A Scoping Review

Pediatric Anesthesia, Volume 36, Issue 9, Page 1041-1051, September 2026.
ABSTRACT Background Intravenous lidocaine therapy (IVLT) is often used in perioperative multimodal analgesia due to its analgesic, anti‐hyperalgesic, and anti‐inflammatory effects. In adults, IVLT doses of 1–2 mg/kg/h produce plasma concentrations of 1–2 μg/mL, within the presumed therapeutic range of 1–5 μg/mL.
McKenna Postles, Amanda Barton, Nicholas West, Gillian Lauder   +3 more
wiley   +1 more source

Transitioning from Transcriptomics to Proteomics: Enhancing Mechanistic Accuracy in PBPK Modeling via Absolute Protein Abundances

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
ABSTRACT Reliable physiologically based pharmacokinetic (PBPK) modeling depends on tissue‐specific expression profiles that reflect protein activities governing drug disposition. In PK‐Sim, existing expression databases rely on transcriptomics data. However, mRNA levels often exhibit limited correlation with protein abundance, frequently necessitating ...
Chen Ning, Alessandra Pugliano, Maximilian Winter, Keliang Wu, Pieter Annaert   +4 more
wiley   +1 more source

Application of Physiologically Based Pharmacokinetic Modeling to Optimize Assessment of Age‐Related Fluoxetine Accumulation in the Elderly

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
ABSTRACT This study quantified age‐related differences in fluoxetine pharmacokinetics and evaluated the influence of CYP2D6 phenotype using physiologically based pharmacokinetic (PBPK) modeling integrated with clinical therapeutic drug monitoring data.
Yoo Jin Jang, Dong‐Gyu Heo, Eunjin Hong   +2 more
wiley   +1 more source

Introduction to Single‐Cell Physiologically‐Based Pharmacokinetic (scPBPK) Models

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
ABSTRACT The current investigation introduces single‐cell physiologically based pharmacokinetic (scPBPK) models to gain insight into drug disposition at the cellular scale. The transition from standard PBPK (sPBPK) models to scPBPK models required depiction of expression‐dependent (ED) processes, such as drug metabolism or membrane transport.
Anshul Saini, James M. Gallo
wiley   +1 more source

Integrated PBPK modelling for PFOA exposure and risk assessment

Environmental Research
Per- and polyfluoroalkyl substances (PFASs) pose significant public health concerns due to their environmental persistence, bioaccumulation, and ubiquitous presence in human biomonitoring (HBM) data, despite regulatory restrictions. This study establishes a deterministic pharmacokinetic model for perfluorooctanoic acid (PFOA), enabling the estimation ...
Karakoltzidis, Achilleas, Karakitsios, Spyros, Gabriel, Catherine, SARIGIANNIS, DIMOSTHENIS   +3 more
openaire   +4 more sources

A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2672-2681, August 2026.
Aim To develop and validate a physiologically‐based pharmacokinetic (PBPK) model enabling inhaled oxytocin dose selection for clinical evaluation. Subsequently, to conduct a phase 1 study investigating the pharmacokinetics and safety of selected doses of an optimized inhaled oxytocin product in healthy, non‐pregnant female participants.
Pete Lambert, Carl M. J. Kirkpatrick, Rory Marriott, Siladitya Ray Chaudhuri, David Polidori, Bart Remmerie, Michelle P. McIntosh   +6 more
wiley   +1 more source